key: cord-0813038-zxz7xc3u
authors: Chatterjee, Debashree; Tauzin, Alexandra; Marchitto, Lorie; Gong, Shang Yu; Boutin, Marianne; Bourassa, Catherine; Beaudoin-Bussières, Guillaume; Bo, Yuxia; Ding, Shilei; Laumaea, Annemarie; Vézina, Dani; Perreault, Josée; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Fournier, Éric; Guilbault, Aurélie; Delisle, Benjamin; Levade, Inès; Goyette, Guillaume; Gendron-Lepage, Gabrielle; Medjahed, Halima; De Serres, Gaston; Tremblay, Cécile; Martel-Laferrière, Valérie; Kaufmann, Daniel E.; Bazin, Renée; Prévost, Jérémie; Moreira, Sandrine; Richard, Jonathan; Côté, Marceline; Finzi, Andrés
title: SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses
date: 2022-02-08
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110429
sha: 58972f9d2ed09067958fa8688db82e0d81cfec05
doc_id: 813038
cord_uid: zxz7xc3u

Continuous emergence of SARS-CoV-2 variants of concern (VOC) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicit antibodies that efficiently recognize Spikes from different VOCs. Here we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naïve and previously infected individuals that received their BNT162b2 mRNA vaccine 16-weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma and Delta Spikes. We compare to plasma activity from participants receiving a short (4-weeks) interval regimen. Plasma from individuals of the long interval cohort recognize and neutralize better the Omicron Spike compared to those that received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.

Continuous emergence of SARS-CoV-2 variants of concern (VOC) is fueling the COVID-37 19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of 38 mutations in its Spike raise concerns about a major antigenic drift that could significantly 39 decrease vaccine efficacy and infection-induced immunity. A long interval between 40

BNT162b2 mRNA doses elicit antibodies that efficiently recognize Spikes from different 41

VOCs. Here we evaluate the recognition of Omicron Spike by plasma from a cohort of 42 SARS-CoV-2 naïve and previously infected individuals that received their BNT162b2 43 mRNA vaccine 16-weeks apart. Omicron Spike is recognized less efficiently than D614G, 44

Alpha, Beta, Gamma and Delta Spikes. We compare to plasma activity from participants 45 receiving a short (4-weeks) interval regimen. Plasma from individuals of the long interval 46 cohort recognize and neutralize better the Omicron Spike compared to those that 47 To get a better understanding of the antigenic profile, we compared the antigenicity of the 145 Omicron Spike to those from D614G, Alpha, Beta, Gamma and Delta VOCs. We used 146 plasma from naïve and previously-infected individuals who received their two doses of 147 the BNT162b2 mRNA vaccine 16 weeks apart. In agreement with previous observations, 148

we found that previously-infected vaccinated individuals recognized more efficiently all 149 J o u r n a l P r e -p r o o f Spikes than naïve individuals at the two timepoints analyzed (3 weeks and 4 months post 150 second dose) (Stamatatos et al., 2021; Tauzin et al., 2022; . 151

Interestingly, we observed that recognition of all Spikes, including Omicron, decreased 152 more rapidly in naïve than previously-infected individuals, as reported (Tauzin et Spike contained the Q493K substitution, but was then corrected to Q493R. Since initial 163 studies on Omicron used the Q493K mutation, we verified whether the nature of the 164 residue at 493 (either K or R) impacted plasma recognition or neutralization. We 165 observed no significant differences among them (Supplemental Figure 2 ). As indicated 166 in the STAR methods section, all results generated in the current manuscript were done 167 using the Q493R mutation. Omicron Spike in previously-infected individuals may be important. This suggests that the 181 benefits of hybrid immunity also apply to Omicron but this hypothesis will need 182 confirmation through vaccine effectiveness studies. 

Further information and requests for resources and reagents should be directed to and 304 will be fulfilled by the lead contact, Andrés Finzi (andres.finzi@umontreal.ca). 305 306 307

All unique reagents generated during this study are available from the Lead contact 309 without restriction. Figure 1 ). Nevertheless, we compared whether the nature 370 of the residue (either K or R) at this position impacted plasma recognition and/or 371 neutralization activity; no significant differences were observed (Supplemental Figure 2) . (A) 293T cells were transfected with the full-length Spikes of Omicron possessing either Q493K or Q493R mutation, stained with the CV3-25 Ab or with plasma collected 3 weeks (V3) after the second dose with a 16-week interval from naïve or previously-infected donors, represented by red and black points respectively and analyzed by flow cytometry. (B) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 Spikes of the two different Omicron mutants as mentioned above, with serial dilutions of plasma collected 3 weeks (V3) after the second dose with a 16-week interval from naïve donors for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID50) values were determined using a normalized nonlinear regression using GraphPad Prism software. Error bars indicate means ± SEM. For each group n=10 donors have been used. Each symbol/points indicates one donor. Statistical significance was tested using a Wilcoxon test (ns, non-significant).

Household transmission of 427 COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-428 control study

SARS-CoV-2 mRNA 431 vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Longitudinal analysis 434 of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 435 months post-symptom onset

Effectiveness of COVID-19 vaccines 438 against the Omicron (B.1.1.529) variant of concern

Antibody cocktail to SARS-CoV-2 spike protein 441 prevents rapid mutational escape seen with individual antibodies

Decline of Humoral 445 Responses against SARS-CoV-2 Spike in Convalescent Individuals

Broadly neutralizing antibodies overcome 448 SARS-CoV-2 Omicron antigenic shift

SARS-CoV-2 Omicron has 451 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires 452 ACE2 for infection

SARS-CoV-2 evolution in an 455 immunocompromised host reveals shared neutralization escape mechanisms

Estimated 459 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

SARS-CoV-2 Spike 462 Expression at the Surface of Infected Primary Human Airway Epithelial Cells

Rapid increase of a SARS-CoV-2 variant with multiple spike protein 465 mutations observed in the United Kingdom

mRNA-based 468 COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron 469 variant

Major role of IgM in the neutralizing 472 activity of convalescent plasma against SARS-CoV-2

Contribution of single mutations to 475 selected SARS-CoV-2 emerging variants Spike antigenicity

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-478 binding domain that affect recognition by polyclonal human plasma antibodies

Mapping mutations to the SARS-CoV-482 2 RBD that escape binding by different classes of antibodies

Complete Mapping of 485 Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody 486 Recognition

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine 489 Dosing Intervals

Isolation and 492 characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

A meta-analysis of Early Results to predict Vaccine efficacy against Omicron

Structural Basis and Mode of Action for Two Broadly

Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern

Potent neutralizing antibodies against multiple epitopes on 503 SARS-CoV-2 spike

Considerable escape 506 of SARS-CoV-2 variant Omicron to antibody neutralization

Reduced sensitivity of 509 SARS-CoV-2 variant Delta to antibody neutralization

Cross-Sectional Evaluation 512 of Humoral Responses against SARS-CoV-2 Spike

Impact of temperature on the affinity 515 of SARS-CoV-2 Spike glycoprotein for host ACE2

A dynamic nomenclature proposal for SARS-CoV-2 lineages to 518 assist genomic epidemiology

Broad and potent 521 activity against SARS-like viruses by an engineered human monoclonal antibody

SARS-CoV-2 spike P681R mutation, a 525 hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

Plasma neutralization 529 properties of the SARS-CoV-2 Omicron variant

High genetic barrier to 532 SARS-CoV-2 polyclonal neutralizing antibody escape

Omicron: A heavily mutated SARS-CoV-2 variant 534 exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic 535 antibodies

CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-539 negative design studies from British Columbia and Quebec, Canada

mRNA vaccination 543 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Prospective mapping of viral mutations that escape 546 antibodies used to treat COVID-19

Introduction of the 548 South African SARS-CoV-2 variant 501Y.V2 into the UK

Strong humoral 551 immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with 552 a 16-week interval between doses

A single dose of the 555 SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T 556 cell responses

Live imaging of SARS-CoV-2 559 infection in mice reveals that neutralizing antibodies require Fc function for optimal 560 efficacy

Rapid epidemic expansion of the SARS-CoV-2 Omicron 563 variant in southern Africa

Escape from neutralizing 567 antibodies by SARS-CoV-2 spike protein variants

Tracking SARS-CoV-2 variants

The significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron